B. Quart

发表

Novel compounds and compositions and methods of use thereof

E. Gunić, J. Girardet, L. Yeh, 2008 .

Clinical potential of a new HIV protease inhibitor.

M. Youle, M Youle, S Chapman, 1995, Journal of the International Association of Physicians in AIDS Care.

Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.

R. Fleischmann, S. Baumgartner, J. Miner, 2014, Rheumatology.

Multicenter trial of sotalol compared with procainamide in the suppression of inducible ventricular tachycardia: a double-blind, randomized parallel evaluation. Sotalol Multicenter Study Group.

M. Scheinman, R. Kehoe, Bramahn . Singh, 1995, American heart journal.

Statistical Methodology for Maximally HIV-RNA Suppressive Treatments in HIV-Infected Subjects

Yueh J. Chang, N. Clendeninn, B. Quart, 2000 .

Relation of blood level and metabolites to the antiarrhythmic effectiveness of encainide.

D. Harrison, R. Kates, B. Quart, 1986, The American journal of cardiology.

577 POSTER Selective MEK Inhibitor RDEA119 exhibits efficacy in orthotopic hepatoma models and cytostatic potential in multiple cell based models of cancer

R. Hamatake, A. Adjei, J. Miner, 2008 .

Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects.

M. Cravets, N. Clendeninn, Kimberly Manhard, 2018, Future oncology.

Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation

M. Cravets, N. Clendeninn, T. Ottoboni, 2018, Drug design, development and therapy.

Sex difference in risk of torsade de pointes with d,l-sotalol.

M. Lehmann, D. Archibald, D. MacNeil, 1996, Circulation.

Treatment of ectopic atrial arrhythmias and premature atrial complexes in adults with encainide.

P. Pool, B. Quart, Barry Quart, 1988, The American journal of cardiology.

Predictors of optimal virological response to potent antiretroviral therapy.

M. Saag, W. Powderly, N. Clendeninn, 1999, AIDS.

Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney

R. Terkeltaub, D. Hagerty, J. Girardet, 2016, Arthritis Research & Therapy.

RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.

R. Hamatake, A. Maderna, T. Appleby, 2009, Cancer research.

Response to the letter to the editor by Hafer and Johnson concerning ‘Mechanism of action of HTX-011: a novel, extended-release, dual-acting local anesthetic formulation for postoperative pain’

J. Dasta, J. Pawasauskas, E. Viscusi, 2020, Regional Anesthesia & Pain Medicine.

The effect of mild alcohol consumption on the metabolism of acetaminophen in man.

P. W. Banda, B. Quart, 1982, Research communications in chemical pathology and pharmacology.

Mechanism of action of HTX-011: a novel, extended-release, dual-acting local anesthetic formulation for postoperative pain

J. Dasta, J. Pawasauskas, E. Viscusi, 2019, Regional Anesthesia & Pain Medicine.

Reduced Pain Intensity and Opioid Consumption for 96 Hours after Abdominoplasty after Administration of HTX-011, a Proprietary, Extended-Release Combination of Bupivacaine and Meloxicam

Sanjay S. Patel, D. Leiman, H. Minkowitz, 2017 .

HTX-011, a Proprietary, Extended-Release Combination of Bupivacaine and Meloxicam, Reduces Acute Postoperative Pain Intensity and Opioid Consumption after Bunionectomy: Results From an Interim Analysis

Sanjay S. Patel, E. Viscusi, E. Onel, 2017 .

Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate.

S. Webber, S Webber, B V Shetty, 1998, Drug metabolism and disposition: the biological fate of chemicals.

Drug interaction studies and encainide use in renal and hepatic impairment.

A. Wood, B. Quart, D. Gallo, 1986, The American journal of cardiology.

Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney

R. Terkeltaub, D. Hagerty, J. Girardet, 2016, Arthritis Research & Therapy.

Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males

C. Storgard, C. Rowlings, L. Yeh, 2015, Drug design, development and therapy.

The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout

S. Baumgartner, L. Yeh, Kimberly Manhard, 2018, Journal of clinical pharmacology.

The use of N-acetylcysteine long after an acetaminophen overdose in mice.

P. W. Banda, B. Quart, 1987, Toxicology letters.

The effect of alcohol on the toxicity of acetaminophen in mice.

P. W. Banda, B. Quart, 1984, Research communications in chemical pathology and pharmacology.

Phase 2a Randomized Controlled Trial of Short-Term Activity, Safety, and Pharmacokinetics of a Novel Nonnucleoside Reverse Transcriptase Inhibitor, RDEA806, in HIV-1-Positive, Antiretroviral-Naïve Subjects

A. Rieger, M. Boffito, G. Moyle, 2010, Antimicrobial Agents and Chemotherapy.

HTX-019 via 2-min injection or 30-min infusion in healthy subjects.

M. Cravets, N. Clendeninn, Kimberly Manhard, 2019, Future oncology.

Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects.

M. Cravets, N. Clendeninn, Kimberly Manhard, 2018, Future oncology.

Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney

R. Terkeltaub, D. Hagerty, J. Girardet, 2016, Arthritis Research & Therapy.